EVE Health Group Limited (ASX:EVE)

Market Cap	5.94M +12.6%
Revenue (ttm)	1.73M -18.7%
Net Income	-1.58M
EPS	-0.01
Shares Out	282.88M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	184,641
Average Volume	354,626
Open	0.0210
Previous Close	0.0210
Day's Range	0.0200 - 0.0210
52-Week Range	0.0180 - 0.0400
Beta	0.29
RSI	48.48
Earnings Date	Feb 26, 2026

About EVE Health Group

EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was...

• Industry: Packaged Foods
• Sector: Consumer Staples
• Founded: 2003
• Employees: 3
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EVE

Financial Performance

In fiscal year 2025, EVE Health Group's revenue was 1.73 million, a decrease of -18.70% compared to the previous year's 2.13 million. Losses were -1.58 million, -16.89% less than in 2024.